Danielle Antalffy's Stock Ratings

UBS Analyst

Danielle Antalffy is an analyst at UBS. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/01/2024

Overall Average Return

4.81%

Smart Score

61.5%

Overall Average Return Percentile

48th

Number of Ratings

71
Buy NowGet Alert
05/16/2024TMCIBuy Now
Treace Medical Concepts
$5.998.51%$16 → $6.5DowngradeBuy → NeutralGet Alert
05/08/2024TMCIBuy Now
Treace Medical Concepts
$5.99167.11%$17 → $16MaintainsBuyGet Alert
05/01/2024SYKBuy Now
Stryker
$341.092.91%$339 → $351MaintainsNeutralGet Alert
04/25/2024BSXBuy Now
Boston Scientific
$75.5719.09%$74 → $90MaintainsBuyGet Alert
04/10/2024DXCMBuy Now
DexCom
$118.7737.24%$153 → $163MaintainsBuyGet Alert
02/16/2024ATRCBuy Now
AtriCure
$22.68155.73%$57 → $58MaintainsBuyGet Alert
02/14/2024INMDBuy Now
InMode
$19.2934.78%$24 → $26MaintainsNeutralGet Alert
01/22/2024ENOVBuy Now
Enovis
$50.2749.19% → $75Initiates → BuyGet Alert
12/01/2023JNJBuy Now
Johnson & Johnson
$146.8622.57% → $180UpgradeNeutral → BuyGet Alert
11/09/2023SYKBuy Now
Stryker
$341.09-12.93%$289 → $297MaintainsNeutralGet Alert
11/03/2023INMDBuy Now
InMode
$19.2924.42%$52 → $24DowngradeBuy → NeutralGet Alert
09/29/2023SWAVBuy Now
ShockWave Medical
$334.80-34.89% → $218Initiates → NeutralGet Alert
09/29/2023TMCIBuy Now
Treace Medical Concepts
$5.99300.67% → $24Initiates → BuyGet Alert
09/29/2023ATRCBuy Now
AtriCure
$22.68146.91% → $56Initiates → BuyGet Alert
09/21/2023BSXBuy Now
Boston Scientific
$75.57-12.66%$63 → $66MaintainsBuyGet Alert
09/06/2023INSPBuy Now
Inspire Medical Systems
$158.79102.78%$405 → $322MaintainsBuyGet Alert
09/06/2023DXCMBuy Now
DexCom
$118.7716.19%$175 → $138MaintainsBuyGet Alert
05/03/2023INSPBuy Now
Inspire Medical Systems
$158.7991.45%$300 → $304MaintainsBuyGet Alert
03/29/2023INMDBuy Now
InMode
$19.29107.36% → $40Initiates → BuyGet Alert
03/29/2023ABTBuy Now
Abbott Laboratories
$102.1514.54% → $117Assumes → BuyGet Alert
03/29/2023DXCMBuy Now
DexCom
$118.7719.56% → $142Initiates → BuyGet Alert
03/29/2023INSPBuy Now
Inspire Medical Systems
$158.7988.93% → $300Initiates → BuyGet Alert
03/29/2023BSXBuy Now
Boston Scientific
$75.57-24.57% → $57Initiates → BuyGet Alert
03/29/2023BFLYBuy Now
Butterfly Network
$0.99126.15% → $2.25Initiates → NeutralGet Alert
03/29/2023BAXBuy Now
Baxter Intl
$33.9526.66% → $43Initiates → NeutralGet Alert
03/29/2023ISRGBuy Now
Intuitive Surgical
$402.12-30.87% → $278Initiates → NeutralGet Alert
03/29/2023JNJBuy Now
Johnson & Johnson
$146.8611.67% → $164Initiates → NeutralGet Alert
03/29/2023TNDMBuy Now
Tandem Diabetes Care
$51.23-12.16% → $45Initiates → NeutralGet Alert
03/29/2023EWBuy Now
Edwards Lifesciences
$86.89-3.33% → $84Initiates → NeutralGet Alert
03/29/2023SYKBuy Now
Stryker
$341.09-15.86% → $287Initiates → NeutralGet Alert

Recent Analyst Stock Rating News

In-Depth Examination Of 6 Analyst Recommendations For DexCom
Peeling Back The Layers: Exploring Stryker Through Analyst Insights
Unveiling 6 Analyst Insights On Treace Medical Concepts
Decoding 18 Analyst Evaluations For Boston Scientific
Cracking The Code: Understanding Analyst Reviews For AtriCure
Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024.
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
Key Takeaways From AtriCure Analyst Ratings
Beyond The Numbers: 13 Analysts Discuss Johnson & Johnson Stock
5 Analysts Have This To Say About Enovis
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free